Ying Ge is a Professor at the University of Wisconsin–Madison, jointly appointed in the Department of Cell and Regenerative Biology and the Department of Chemistry. Her research integrates chemistry, biology, and medicine, focusing on advanced mass spectrometry-based proteomic and metabolomic technologies to address cardiovascular diseases. Education: B.S., Peking University (1997) Ph.D., Cornell University (2002) Ying Ge's work centers on developing ultra high-resolution mass spectrometry platforms for top-down proteomics and metabolomics, applied to systems biology studies of heart failure and regenerative medicine. Key projects include myofilament protein modification mapping, stem cell therapy evaluation, and biomarker discovery for cardiac conditions. The 15 most recent articles highlight her lab's methodological innovations (e.g., photocleavable surfactants, native mass spectrometry) and biological discoveries in AMPK structural heterogeneity, RBM20-mediated cardiotoxicity, and sarcomere-metabolism cross-talk during regeneration. These publications span proteomics, metabolomics, structural biology, and clinical applications.
جستوجوی استاد و پژوهشگر
استاد راهنما، استاد دانشگاه یا پژوهشگر مناسب برای مسیر پژوهشیتان را پیدا کنید و با او ارتباط بگیرید.
نمایش ۶۱-۷۵ از ۷٬۸۸۵ استاد راهنما
اطلاعات این پروفایلها از صفحات عمومی دانشگاهها جمعآوری شده و ممکن است بهروز نباشد.
Iona Cheng is a Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), where she conducts groundbreaking research in cancer epidemiology. She serves as co-Investigator of the SEER Greater Bay Area Cancer Registry and is Principal Investigator of multiple NIH- and foundation-funded projects examining genetics, lifestyle factors, and neighborhood characteristics in relation to cancer risk. Dr. Cheng has developed an extensive research program focused on racial/ethnic differences in cancer risk and leads population-based cancer surveillance studies that document variations in cancer incidence and mortality patterns across diverse racial and ethnic groups. University of California, Davis, BS, 1990–1994, Physiology Yale University, MPH, 1999–2001, Chronic Disease Epidemiology University of Southern California, PhD, 2001–2005, Epidemiology University of California, San Francisco, Postdoc, 2006–2008, Genetic and Molecular Epidemiology Dr. Cheng's research spans multiple disciplines within cancer epidemiology, with particular emphasis on understanding how environmental exposures, genetic factors, and social determinants interact to influence cancer risk and outcomes across different racial and ethnic populations. Her work frequently examines the impact of air pollution, endocrine-disrupting chemicals, and neighborhood characteristics on cancer development and survival. She has made significant contributions to understanding cancer disparities among Asian American, Native Hawaiian, and Pacific Islander populations, bringing attention to the unique cancer risks and outcomes within these understudied groups. Her research often leverages the Multiethnic Cohort Study, one of the largest prospective studies of cancer incidence and mortality across diverse racial/ethnic populations. Analysis of Dr. Cheng's recent publications reveals a consistent focus on environmental and social determinants of cancer risk across multiple organ sites. Her work demonstrates a sophisticated integration of epidemiological methods with environmental exposure assessment, genetic analysis, and health disparities research. Many of her studies examine the intersection of environmental exposures and racial/ethnic disparities in cancer outcomes, particularly regarding breast cancer, lung cancer, and other malignancies. She has published extensively on the impact of air pollution on cancer risk and survival, as well as the effects of endocrine-disrupting chemicals like bisphenol A, parabens, and phthalates. American Association for Cancer Research Scholar-in-Training Award (2007) National Institutes of Health Loan Repayment Award (2007) National Institutes of Health Loan Repayment Renewal Award (2009) American Association for Cancer Research Faculty Scholar Award (2011) National Institutes of Health Loan Repayment Renewal Award (2011) National Institutes of Health Loan Repayment Renewal Award (2013) American Journal of Epidemiology/Society of Epidemiology Research Top 10 manuscripts (2014) Cancer Prevention Institute of California Mentoring Award (2015) American Society of Human Genetics Top poster As Principal Investigator of multiple NIH-funded projects, Dr. Cheng oversees substantial research grants focused on cancer epidemiology and health disparities. Her work often involves large interdisciplinary collaborations with researchers across multiple institutions, including the Multiethnic Cohort Study which follows over 200,000 participants from diverse racial/ethnic backgrounds. She has demonstrated leadership in mentoring junior researchers, particularly those from underrepresented backgrounds in science, as evidenced by her Cancer Prevention Institute of California Mentoring Award. Her research program integrates data from cancer registries, electronic health records, and geospatial information to provide comprehensive insights into cancer patterns and risk factors. Dr. Cheng's research is closely connected to the UCSF Helen Diller Family Comprehensive Cancer Center and leverages collaborations with Lawrence Berkeley National Laboratory, which provides advanced technological resources for cancer research. Her work benefits from access to extensive cohort data, sophisticated exposure assessment methods, and interdisciplinary expertise in genetics, environmental science, and computational biology available through these institutional partnerships. She frequently collaborates with researchers studying the genetic and environmental determinants of cancer across multiple organ systems, contributing to a more comprehensive understanding of cancer etiology and prevention strategies.
Gustavo Nader, Ph.D., is a Professor of Kinesiology at The Pennsylvania State University's College of Health and Human Development, where he holds the Dorothy Foehr Huck and J. Loyd Huck Endowed Chair in Molecular, Cellular and Integrative Physiology. His research laboratory at 101 Noll Lab focuses on molecular mechanisms of skeletal muscle adaptation, employing human, animal, and cellular models to investigate ribosome biogenesis, transcriptional regulation, and muscle growth control in contexts ranging from exercise hypertrophy to cancer cachexia. Dr. Nader's research examines fundamental processes including: Ribosome biogenesis and its role in muscle growth regulation Epigenetic control of RNA Polymerase I activity Molecular pathways in mechanical overload-induced hypertrophy Tumor-induced muscle wasting mechanisms Biomimicry approaches inspired by hibernator physiology His work spans exercise physiology, cancer biology, and environmental stress responses. Analysis of his 15 most recent publications (2015-2025) reveals predominant themes in muscle hypertrophy mechanisms, cancer cachexia pathophysiology, ribosomal function analysis, and environmental stress impacts on muscle. His work consistently integrates molecular techniques with physiological models across species. Notable scientific recognitions include: Dorothy Foehr Huck and J. Loyd Huck Chair appointment (2024) Huck Institutes Leadership Fellowship (2025-2026) Dr. Nader leads an active research team investigating muscle plasticity, with current projects funded through the Huck Institutes of the Life Sciences. He collaborates extensively through Penn State's Integrative and Biomedical Physiology graduate program and Center for Cellular Dynamics.
Kurt Schalperمشاهده پروفایل
دانشیار
Kurt Schalper, MD, PhD is an Associate Professor of Pathology at Yale School of Medicine and Director of the Translational Immuno-Oncology Laboratory (T.I.L.) at Yale Cancer Center. His primary appointment is in the Department of Pathology with secondary appointments in Medical Oncology and Hematology. Dr. Schalper maintains affiliations with multiple cancer research entities including the Cancer Immunology Program, Yale Center for Immuno-Oncology, and the Yale Combined Program in the Biological and Biomedical Sciences (BBS). Dr. Schalper trained as a cell biologist and surgical pathologist, completing his MD at San Sebastian University (2003) and PhD at Universidad Catolica de Chile (2008). His postdoctoral work at Yale focused on developing quantitative strategies to measure immunotherapy-related biomarkers in immune cells and cancer tissues. His research centers on understanding the immunobiology of human solid tumors, particularly lung cancer, with emphasis on immune evasion mechanisms, tumor microenvironment dynamics, and biomarker development for immunotherapy response prediction. Current scientific interests include tumor immune heterogeneity, editing, and the role of specific tumor antigens and immune evasion pathways in lung malignancies. Analysis of Dr. Schalper's recent publications reveals a strong focus on immuno-oncology, particularly in lung cancer. His work spans biomarker development, mechanisms of immunotherapy resistance, tumor microenvironment characterization, and clinical translation of immunotherapeutic approaches. Notable themes include the investigation of KEAP1/STK11-related resistance, IL-4 mediated immune evasion, and strategies to overcome immunotherapy resistance through combination approaches. Dr. Schalper collaborates extensively with Yale researchers, particularly with Dr. David Rimm (57 common publications), Dr. Roy S. Herbst (35 common publications), Dr. Scott Gettinger (14 common publications), and Dr. Sarah Goldberg (12 common publications). His work appears in high-impact journals including Nature, Journal of Clinical Investigation, and Nature Reviews Clinical Oncology. As Director of the Translational Immuno-Oncology Laboratory, Dr. Schalper leads efforts to produce and support high-quality translational research in immuno-oncology through standardized biomarker analyses and integration with Yale resources. His laboratory focuses on developing quantitative methods for immunotherapy biomarker assessment and understanding mechanisms of response and resistance to cancer immunotherapies.
Prof. Dr. Michael Schloter serves as Director of the Research Unit for Comparative Microbiome Analysis at Helmholtz Munich since 2011 and holds a Professorship in Microbiology at the Technical University of Munich since 2010. He concurrently acts as Principal Investigator at both the German Center for Lung Diseases (DZL) and the Central for Food and Nutrition (ZIEL) at TU Munich, driving interdisciplinary research at the intersection of environmental and human health through the "Planetary Health" framework. His educational foundation was built through diploma studies at Ludwig Maximilian University Munich and doctoral research at the University of Bayreuth, followed by formative work in Brazil and the United States where he pioneered bioinocula development for stress-resilient agriculture. At Helmholtz Munich (formerly GSF), he evolved from group leader in soil microbial ecology (2001) to Research Unit Director, expanding his focus from agricultural systems to human microbiome-health connections. Dr. Schloter's research program centers on microbiome-host crosstalk across ecological scales, investigating how environmental microbiota interact with human and plant microbiomes to influence health outcomes. His work integrates ecological theory with microbiome analysis to decode host-microbe co-evolution patterns, with applications spanning sustainable agriculture, allergy prevention, and infection control. Key thematic pillars include holobiont theory, probiotic development, and microbiome-mediated disease prevention through environmental quality improvement. Analysis of his 2025 publications reveals a strategic research portfolio bridging fundamental and applied microbiome science. Agricultural studies dominate (maize, potato, apple systems), examining microbial inoculants and soil management, while human health investigations explore preterm birth complications and Antarctic mammal microbiomes. Computational approaches for antimicrobial resistance assessment and ecosystem-scale projects like JenaTron demonstrate methodological breadth, all converging on translating microbiome functionality into real-world sustainability solutions. Major recognitions include: Election to the Bavarian Academy of Science (2021) Consistent placement among the top 1% of highly cited global researchers (2019-2021) Heinrich Baur Research Award (2011) for agricultural microbiology contributions As Research Unit Director, Schloter leads large-scale collaborative initiatives including the DZL and ZIEL consortia, securing major funding for microbiome standardization projects and international research networks. His leadership extends to developing analytical frameworks for cross-ecosystem microbiome comparisons and establishing protocols for translating microbial ecology principles into clinical and agricultural applications. The Comparative Microbiome Analysis unit operates as a nexus for multi-host microbiome research, employing comparative genomics, field-scale agricultural trials, and clinical cohort studies to investigate microbiome dynamics across environmental, plant, and human systems. Current infrastructure includes advanced sequencing facilities and experimental platforms for plant-microbe and host-microbe interaction studies under controlled and natural conditions.
Professor Lars E. Eriksson is a Registered Nurse with a PhD in Nursing and an MSc in Chemistry, currently serving as a part-time Professor in Nursing at the School of Health and Medical Sciences, City St George's, University of London, and as a full Professor in Nursing at Karolinska Institutet, Stockholm, Sweden, where he leads the Lars E. Eriksson Research Group. His academic journey began with a UC in Nursing in 1985, followed by over a decade of clinical work in hematology, immunology, and HIV care in Stockholm, before transitioning into research and academia. His research is centered on biobehavioral and translational nursing, particularly focusing on health and quality of life among individuals with chronic conditions such as HIV, cancer, and long-term infections. Key areas include disease-related stigma, symptom research, patient-reported outcomes, and biomarker development. He is Principal Investigator for a lung cancer biomarker project funded by the Swedish Research Council and the Swedish PI for the H2020 Magnet4Europe project on mental health in healthcare workplaces. His recent publications show a strong trend in using mixed methods to explore end-of-life communication, death literacy, sexual and reproductive health after cancer, and stigma in chronic illness. He frequently employs patient-reported outcomes, online focus groups, and web-based interventions, often in collaboration with international partners. His work bridges clinical practice, nursing science, and public health. Scientific Awards and Memberships: British HIV Association (BHIVA) National HIV Nurses Association (NHIVNA) Swedish Society of Nursing Swedish Society of Medicine Swedish Society of Medical Microbiology Lars Eriksson has advised numerous PhD and Master’s students, primarily on topics related to quality of life, stigma, and chronic illness. He teaches postgraduate modules including MSc Dissertation, Advanced Practice Dissertation, and Sexual and Reproductive Health. He is affiliated with the Centre for Health Services Research and the Centre for Public Health Research at City St George's.
- Nanoscience
- Inorganic Chemistry
- Materials Science
- +۷ مورد دیگر
John Capobianco, PhD, is a Professor in the Department of Chemistry and Biochemistry at Concordia University and holds the Honorary Concordia University Research Chair in Nanoscience. His research focuses on lanthanide-doped nanoparticles, upconversion luminescence, and biomedical applications. PhD, University of Geneva Key research areas include: Nanomaterials synthesis and spectroscopy Upconversion for biomedical imaging Drug delivery systems Photodynamic therapy for cancer treatment Optical thermometry and sensing Recent publications highlight advancements in: X-ray detection via photochromic nanoparticles Lipid-coated nanoparticles for lung permeation Cooperative energy transfer in Yb3+/Eu3+ complexes Biocompatible nanomaterials for secure information storage Pr3+-doped radiosensitizers for glioblastoma therapy Scientific recognitions: Honorary Concordia University Research Chair in Nanoscience Teaching includes undergraduate and graduate courses in inorganic chemistry and spectroscopy. His work bridges fundamental material science with applied biomedical engineering, emphasizing optical properties and therapeutic applications of lanthanide-based nanomaterials.
Prof. Dr. Urs F. Greber is an Ordinary Professor of Molecular Cell Biology at the Department of Molecular Life Sciences, Faculty of Mathematics and Natural Sciences, University of Zurich. His research focuses on understanding how viruses interact with host cells, particularly adenoviruses and rhinoviruses that cause human respiratory diseases. He leads the Greber Lab, which investigates viral entry mechanisms, replication processes, and the cellular responses to infection. Greber's research interests span virology, molecular cell biology, and infection mechanisms. His lab explores how viruses take control over membrane and lipid functions, cytoplasmic transport processes, and cellular metabolism to support their gene expression and progeny formation. They employ system-wide profiling, molecular cell biology approaches, light microscopy, and machine learning for image analysis to map the cell state underlying viral infections of cultured and primary human cells, including lung organoids and iPSC-derived macrophages. A key focus is understanding cell-to-cell variability in infection phenotypes and the mode-of-action of antiviral compounds. The Greber Lab has published extensively on adenovirus biology, including viral entry, uncoating, nuclear import, and assembly mechanisms. Their recent work has identified broad-spectrum antiviral compounds, elucidated alternative virus entry pathways, and developed innovative imaging and AI-based approaches for quantifying virus infectivity. Their research contributes to understanding how viruses break down host defense barriers and has implications for antiviral therapy development. Greber has supervised numerous PhD and Master's students including Cornelia Bircher, Alessandro Savi, Franziska Tomas, Alfonso Gomez-Gonzalez, Anthony Petkidis, and Dominik Olszewski. His lab has received funding from the Swiss National Science Foundation, including a grant for coronavirus research during the pandemic. The lab actively collaborates with other research groups at University of Zurich, ETH Zurich, and international institutions. Current projects include exploring how viral DNA interactions contribute to infection outcome variability, investigating adenovirus egress mechanisms, and developing high-throughput screening methods for antiviral compounds.
Meisam Asgariمشاهده پروفایل
استادیار
Meisam Asgari is an Assistant Professor in the Department of Medical Engineering at the University of South Florida. He holds a Ph.D. in Mechanical Engineering from McGill University (2015), with postdoctoral training at Northwestern University (2018–2020) and McGill University (2016–2018). His research focuses on biomechanics, cardiovascular diseases, biomimetic design, and functional gradients in biological materials. He teaches courses such as Transport Phenomena in Biomedical Engineering and Biomechanics. Education: Ph.D. Mechanical Engineering, McGill University, 2015 M.Sc. Solid Mechanics, Isfahan University of Technology, 2011 B.Sc. Mechanical Engineering, Isfahan University of Technology, 2007 Awards: NSERC Postdoctoral Fellowship (2018–2020) McGill Engineering International Tuition Award (2011–2014) Outstanding Teaching Assistant Award, McGill (2015) His research integrates experimental and computational methods to study vascular diseases, biomaterials for tissue engineering, and structural adaptations in biological systems like crustacean exoskeletons. Recent work includes developing decellularized aortic grafts and investigating collagen mechanics in diseased tissues. Publications span Acta Biomaterialia , Scientific Reports , and Journal of the Mechanical Behavior of Biomedical Materials , emphasizing biomechanics and material characterization. His work bridges engineering and biology to address clinical challenges in cardiovascular and musculoskeletal systems.
Dr. Joshua Brinkerhoff is an Associate Professor in Mechanical Engineering at the University of British Columbia Okanagan Campus. He serves as the Associate Director for Research & Industrial Partnerships in the School of Engineering and leads the UBC-Okanagan Computational Fluid Dynamics Laboratory. His research spans computational fluid dynamics, turbomachinery, multiphase flows, hydrogen safety, wind energy, and biofluid mechanics. He teaches courses in mechanics of materials, alternative energy systems, turbulence, computational fluid dynamics, and aircraft design. PhD, Aerospace Engineering (Carleton University, Ottawa, ON) BEng, Aerospace Engineering (Carleton University) Dr. Brinkerhoff’s research interests include: Computational Fluid Dynamics (CFD) for laminar-to-turbulent transition and instability analysis Wind energy systems and turbine aerodynamics Hydrogen storage and safety protocols for transportation Biofluid mechanics for respiratory diseases and aneurysm modeling Multiphase flows in industrial and environmental contexts His publications focus on CFD simulations for: Aerosol dispersion and mitigation in indoor environments Wind farm interactions and atmospheric gravity waves Cavitation and phase transitions in cryogenic and LNG systems Heat transfer optimization in industrial and thermal systems Instability dynamics in buoyancy-driven and swept flows Turbulent structures in fluidized beds and reactors Dr. Brinkerhoff has no listed scientific awards in the provided data but has extensive contributions to renewable energy, hydrogen safety, and medical fluid dynamics. His laboratory develops open-source tools like TOSCA for large-eddy simulations and investigates practical applications in urban air quality, dental aerosol control, and turbine wake modeling.
Dr. James W. Navalta is an Associate Professor in the Department of Kinesiology and Nutrition Sciences at the University of Nevada, Las Vegas. His research focuses on physiological responses to outdoor exercise (hiking, trail running) and the validity/reliability of wearable technology. He earned his B.S. in Physical Education and Biology from Brigham Young University–Hawaii, M.S. in Kinesiology from UNLV, and Ph.D. in Exercise Physiology from Purdue University. Education: B.S. - Physical Education & Biology, Brigham Young University–Hawaii M.S. - Kinesiology, University of Nevada, Las Vegas Ph.D. - Exercise Physiology, Purdue University His research portfolio includes: Wearable technology validation for physiological measurements Comparative studies of indoor vs outdoor exercise environments Impact of gender-inclusive approaches on sports science Metabolic and cardiovascular responses to unconventional workouts Psychological benefits of nature immersion Recent publications demonstrate expertise in: Wearable device accuracy testing VO2max and lactate threshold validation Environmental influence on exercise physiology Methodological improvements in data collection Gender-inclusive research design Outdoor activity impact assessment As co-founder and executive editor of the International Journal of Exercise Science, he contributes significantly to academic discourse. He also serves on editorial boards for journals related to digital health and exercise technology.
Anthony A Gattiمشاهده پروفایل
پژوهشگر ارشد
- Biomechanics
- Medical Imaging
- Machine Learning
- +۷ مورد دیگر
Anthony A Gatti is a Postdoctoral Scholar at Stanford University's Wu Tsai Human Performance Alliance and School of Medicine. His research integrates biomechanics , medical imaging , and machine learning to advance musculoskeletal health diagnostics, particularly focusing on knee osteoarthritis and exercise physiology. Education : Ph.D. in Rehabilitation Science (McMaster University, 2021), M.Sc. in Rehabilitation Science (McMaster University, 2015), B.Sc. in Kinesiology (McMaster University, 2013) His research develops automated tools for quantifying knee anatomy and integrating anatomical data with biomechanical models . These methods analyze acute responses to exercise and long-term joint degeneration, leveraging MRI , deep learning , and statistical shape modeling . Recent publications emphasize AI-driven segmentation , exercise-induced cartilage changes , and biomechanical simulations , spanning journals like Magnetic Resonance in Medicine and Arthritis & Rheumatology . Trends include machine learning validation for clinical predictions and open-source tool development for musculoskeletal analysis. Scientific Awards : CIHR Postdoctoral Fellowship (top 1%), Mitacs Accelerate Entrepreneur, Forge Student Start-Up Competition Winner, multiple scholarships from McMaster University He founded NeuralSeg , a company commercializing deep learning-based MRI segmentation technology. Collaborations include Stanford's Digital Athlete Moonshot Project with advisors like Scott Delp and Garry Gold.
Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition
Kumar Somyajitمشاهده پروفایل
دانشیار
Kumar Somyajit is Associate Professor at the University of Southern Denmark's Department of Biochemistry and Molecular Biology. He leads research on DNA replication and genome surveillance mechanisms using mammalian cell models. Research focuses on: Metabolic regulation of DNA replication Replisome plasticity under stress Homology-directed repair mechanisms Chromatin dynamics in cancer Recipient of Lundbeck Foundation Fellowship (2021). Current projects investigate metabolic coupling to genome surveillance in cancer and development. Supervises PhD students in DNA repair and replication studies.
Igor Jurisica is a Professor at the University of Toronto and a Senior Scientist at the Krembil Research Institute’s Data Science Discovery Centre for Chronic Diseases. He also serves as Visiting Scientist at IBM CAS, Scientific Director of the World Community Grid, and Chief Scientist at the Creative Destruction Lab (Rotman School of Management). His research focuses on integrative computational biology, data mining, and AI-driven models for cancer mechanisms, drug discovery, and chronic disease management. Key affiliations include the Osteoarthritis Research Program, Schroeder Arthritis Institute, and leadership roles in open science initiatives like the World Community Grid, a global distributed computing platform with 810,000+ volunteers. Jurisica’s work bridges computational tools (e.g., NAViGaTOR visualization platform, MirDIP databases) and clinical applications, emphasizing explainable AI in healthcare. Research interests span proteomics, microRNA regulation, systems vaccinology, and multi-omics integration for disease stratification. Notable contributions include identifying prognostic signatures in cancer and osteoarthritis, machine learning models for drug repurposing, and sportomics analyses of athletic biomarkers. He has been recognized as a Thomson Reuters Highly Cited Researcher (2014-2016) and ranked among the Top 100 AI Leaders in Oncology (2023). His labs develop open-access tools like PathDIP, OsteoDIP, and miRAnno to advance translational research.